Quick View
| Indicator | Current Period | Same Period Last Year | YoY |
|---|---|---|---|
| Revenue | ¥132.0B | ¥119.3B | +10.6% |
| Operating Income | ¥8.4B | ¥6.2B | +35.4% |
| Ordinary Income | ¥7.8B | ¥4.4B | +79.3% |
| Net Income | ¥3.5B | −¥1.5B | +329.2% |
| ROE | 1.1% | −0.5% | - |
Executive Summary
In Q1 FY2026, revenue and profit increased owing to higher revenue and improved margins in the core Healthcare Business; however, profit attributable to owners of the parent remained in the red due to the impact of tax expenses and profit attributable to non-controlling interests. Revenue was ¥132.0B (¥119.3B in the same period last year, +10.6% YoY), Operating Income was ¥8.4B (¥6.2B, +35.4%), and Ordinary Income was ¥7.8B (¥4.4B, +79.3%). Net Income (on a consolidated basis, including the portion attributable to non-controlling interests) was ¥3.5B, representing a return to profitability from △¥1.5B in the same period last year; however, the quarterly net loss attributable to owners of the parent was ¥0.3B. Operating Income growth exceeding revenue growth was primarily attributable to fixed-cost absorption and margin improvement, in addition to increased revenue in the Healthcare Business.
Factors Affecting Performance
【Revenue】Revenue was ¥132.0B, an increase of +10.6% YoY. By segment, the Healthcare Business led overall performance with revenue of ¥121.9B (92.3% of total revenue, +11.6% YoY), while the Biofuel Business generated ¥2.6B (+1.6%) and Other Businesses generated ¥7.6B (△0.9%), both showing limited growth. Within the Healthcare Business, OEM, Raw Materials, and Overseas generated ¥25.0B, representing strong growth of +52.0% YoY and serving as a growth driver that complemented Direct Sales of ¥87.1B (+5.2%).
【Profit and Loss】Operating Income was ¥8.4B, up +35.4% YoY, and the Operating Income Margin improved to 6.3% from approximately 5.2% in the same period last year. Segment profit in the Healthcare Business was ¥15.0B (+24.6%), with a margin of 12.3%, up from approximately 11.0% in the same period last year, making it the primary driver of the improvement in the consolidated profit margin. Meanwhile, the segment loss in the Biofuel Business widened to ¥1.3B from ¥0.5B in the same period last year, while the loss in Other Businesses also widened to ¥1.1B. Ordinary Income was ¥7.8B (+79.3%), benefiting from improved non-operating income and expenses in addition to higher Operating Income. Against Profit Before Tax of ¥7.8B, Corporate Income Taxes and Other amounted to ¥4.3B, while profit attributable to non-controlling interests amounted to ¥3.9B, resulting in a net loss of ¥0.3B attributable to owners of the parent. In conclusion, the Company is in a phase of revenue and profit growth, but the conversion of earnings into profit attributable to owners of the parent remains a challenge.
Segment Analysis
The Healthcare Business posted higher revenue and profit, with revenue of ¥121.9B (+11.6% YoY) and segment profit of ¥15.0B (+24.6%), and serves as the core contributor to consolidated profit. The Biofuel Business generated only ¥2.6B in revenue (+1.6%), while its segment loss widened to ¥1.3B from ¥0.5B in the same period last year. Other Businesses also experienced a decline in revenue, generating ¥7.6B (△0.9%), while the loss widened to ¥1.1B. Growth in consolidated Operating Income is highly dependent on the Healthcare Business, and improving the profitability of the two loss-making businesses will be a prerequisite for future profit growth.
Key Financial Indicators
【Profitability】The Operating Income Margin improved to 6.3% from approximately 5.2% in the same period last year; however, the SG&A ratio of 61.8% remains high relative to the strong gross margin of 68.1%, indicating that operating leverage is not yet working sufficiently. ROE remained at 1.1%, depressed by the high effective tax rate in the conversion from Profit Before Tax to profit attributable to owners of the parent, as well as the presence of profit attributable to non-controlling interests.【Cash Flow Quality】Cash and deposits were ¥188.7B, slightly below short-term borrowings of ¥192.8B, warranting close monitoring of short-term liquidity.【Investment Efficiency】Intangible fixed assets were ¥303.8B and goodwill was ¥109.2B, accounting for 43.0% and 15.5% of total assets, respectively. Monetization of acquired assets will be key to improving ROIC.【Financial Soundness】While the Equity Ratio improved to 43.6% from 42.7% in the same period last year, the Current Ratio of 117.0% and Quick Ratio of 107.9% remain at levels that only narrowly cover short-term liabilities.
Cash Flow Analysis
Although detailed disclosure of the cash flow statement is not available, an analysis of funding trends based on changes in the balance sheet shows that cash and deposits declined to ¥188.7B from ¥211.6B in the same period last year, while short-term borrowings rose substantially to ¥192.8B from ¥39.4B. During this period, long-term borrowings declined sharply from ¥179.2B to ¥23.4B, indicating a change in the funding structure involving the transfer of long-term funding to short-term funding. Net assets increased to ¥308.0B from ¥285.3B in the same period last year, and the Equity Ratio also improved to 43.6%, indicating an improving financial position from a capital perspective. Nevertheless, the increased dependence on short-term borrowings is a key point to monitor in terms of future liquidity and refinancing trends.
Earnings Quality
The divergence between Ordinary Income of ¥7.8B and Net Income (△¥0.3B attributable to owners of the parent) was primarily due to tax expenses and profit attributable to non-controlling interests, with almost no extraordinary income or expenses arising on a temporary basis (extraordinary income: ¥0.0B). Of non-operating income of ¥1.5B and non-operating expenses of ¥2.1B, interest expenses of ¥1.5B were the primary item and are recurring financing costs. Corporate Income Taxes and Other of ¥4.3B were recorded against Profit Before Tax of ¥7.8B, resulting in a high effective tax rate of approximately 54.7%. In addition, profit attributable to non-controlling interests of ¥3.9B was deducted, meaning that profit growth at the operating level was not sufficiently reflected in profit attributable to owners of the parent. Comprehensive income was ¥5.3B, with a positive foreign currency translation adjustment of ¥1.6B contributing to the result; however, the portion attributable to owners of the parent was only ¥1.4B, while the ¥3.9B attributable to non-controlling interests accounted for the majority of comprehensive income, a point that warrants attention when assessing earnings quality.
Earnings Forecasts and Guidance
The full-year Company plan calls for Revenue of ¥520.0B (+3.2% YoY), Operating Income of ¥32.0B (+2.5%), and Ordinary Income of ¥28.0B (+18.4%). Progress against the full-year plan in Q1 was 25.4% for Revenue, 26.2% for Operating Income, and 27.9% for Ordinary Income, each slightly exceeding a simple 25% run rate. However, the degree of outperformance was small, and the results remain at a level that can be viewed as being in line with the full-year plan. No revision has been made to the earnings forecasts.
Shareholder Returns
The full-year dividend forecast is ¥0.0 per share, with no revision to the dividend forecast as of the end of the quarter. Given that the quarterly net loss attributable to owners of the parent was ¥0.3B and the Company has a high level of dependence on short-term borrowings, no shareholder returns through cash dividends are currently planned.
Risk Factors
-
Profit Concentration Risk: While the Healthcare Business forms the core of consolidated profit with segment profit of ¥15.0B, losses in the Biofuel Business (loss of ¥1.3B) and Other Businesses (loss of ¥1.1B) are widening. The high dependence on the core business is therefore a source of volatility in consolidated earnings.
-
Short-Term Funding Risk: Cash and deposits of ¥188.7B do not fully cover short-term borrowings of ¥192.8B. The Current Ratio against current liabilities of ¥275.4B is 117.0%, indicating a structure that is susceptible to refinancing conditions and interest-rate trends.
-
Intangible Asset Concentration and Tax Burden Structural Risk: Intangible fixed assets of ¥303.8B and goodwill of ¥109.2B account for 43.0% and 15.5% of total assets, respectively, creating potential impairment risk if monetization stagnates. In addition, due to the effective tax rate of approximately 54.7% and profit attributable to non-controlling interests of ¥3.9B, the efficiency of conversion from Profit Before Tax to profit attributable to owners of the parent remains low.
Industry Benchmark (Reference; Compiled by the Company)
Profitability and Returns
| Indicator | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Income Margin | 6.3% | – | – |
| Net Income Margin | 2.7% | – | – |
As industry median data for the Company’s profitability indicators has not been provided, comparative analysis is not currently possible.
Growth and Capital Efficiency
| Indicator | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 10.6% | – | – |
Industry median data for growth has likewise not been provided; therefore, only the Company’s standalone figures are disclosed.
※Source: Compiled by the Company
Key Points from the Earnings Results
-
Operating Income growth of +35.4% exceeded Revenue growth of +10.6%, and improvement in the Healthcare Business’s margin (12.3%, approximately +1.3pt YoY) drove consolidated profitability. This was the defining feature of the current period.
-
The net loss attributable to owners of the parent was limited to ¥0.3B, while the substantial increase in Ordinary Income was offset by the high effective tax rate and profit attributable to non-controlling interests. This structure will remain an ongoing point of review in assessing future earnings quality.
-
Q1 progress against the full-year plan was 25.4% for Revenue, 26.2% for Operating Income, and 27.9% for Ordinary Income, indicating progress in line with the plan.
This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
FY2026 Q1 showed a clear operating improvement, although profit attributable to owners of the parent remained marginally negative. Revenue increased 10.6% YoY to ¥13.20bn. Operating income rose 35.4% to ¥0.84bn, outperforming sales growth. Ordinary income increased 79.3% to ¥0.78bn, aided by the absence of the prior-year foreign-exchange loss and higher non-operating income. The gross margin was 68.1%, down 169bp from 69.8% a year earlier as cost of sales grew faster than revenue. Nevertheless, the SG&A ratio declined by about 290bp to 61.8%, because SG&A rose only 5.7% YoY. Consequently, the operating margin expanded 116bp to 6.3% from 5.2%. The ordinary margin improved 228bp to 5.9%. Healthcare was the earnings engine, with segment profit rising 24.6% to ¥1.50bn. Biofuel remained loss-making and its segment loss widened to ¥0.13bn from ¥0.05bn. Other businesses also remained loss-making, with a segment loss of ¥0.11bn. The parent-attributable result was a ¥0.03bn loss despite ¥0.35bn consolidated net income, because ¥0.39bn of profit was attributable to non-controlling interests. Income tax expense of ¥0.43bn absorbed 54.7% of pre-tax income and exceeded the profit available to parent shareholders, producing a 104% effective rate on parent-attributable pre-tax earnings. The balance sheet became more short-term-debt dependent following a substantial shift from long-term to short-term borrowings. Liquidity remains positive, with a 117.0% current ratio and cash of ¥18.87bn, but cash covers only 0.98x short-term debt. Full-year guidance was maintained, and Q1 progress is broadly in line with the annual plan. The central forward issue is whether Healthcare's scalable direct-sales and OEM growth can continue to offset persistent biofuel and other-business losses, while refinancing risk and the large intangible asset base are managed.
Profitability Analysis
The reported annualized DuPont ROE is -0.4%, decomposed into a -0.2% net profit margin, 0.747x asset turnover, and 2.29x financial leverage. The negative net margin is the binding constraint on shareholder returns: operating profitability was positive, but tax expense and the allocation of consolidated earnings to non-controlling interests resulted in a ¥0.03bn loss attributable to owners. Financial leverage is meaningful but does not offset the negative parent-attributable margin. Asset turnover of 0.747x is modest, reflecting an asset base with ¥30.38bn of intangible assets and ¥10.92bn of goodwill. The largest operating improvement was margin expansion, rather than leverage or turnover. Revenue grew 10.6%, while SG&A grew 5.7%, creating positive operating leverage and expanding the operating margin by 116bp to 6.3%. Gross margin compressed 169bp to 68.1%, indicating that the operating-margin improvement came from overhead absorption and spending discipline rather than improved product gross profitability. Healthcare segment revenue increased 5.4% to ¥12.19bn and segment profit increased 24.6% to ¥1.50bn, making it the core business and the principal contributor to consolidated operating income. Within Healthcare, direct sales grew 5.2% to ¥8.71bn, distribution was broadly flat at ¥0.97bn, and OEM, raw-material and overseas sales rose 52.0% to ¥2.50bn. This channel mix suggests that OEM/raw-material/overseas expansion was the principal incremental revenue driver. Healthcare segment margin improved to 12.3% from 11.0%, whereas Biofuel and Other remained loss-making. The ¥0.13bn Biofuel loss and ¥0.11bn Other loss, together with ¥0.42bn of unallocated corporate costs, limit conversion of gross profit into group operating income. Interest coverage of 5.54x is adequate but leaves limited room for a material rise in borrowing costs. The quality alert for capital efficiency is justified: ROIC of approximately 5.0% is at the low end of the stated benchmark and implies that returns on the large capital and acquisition-related asset base remain modest.
Growth Assessment
Revenue growth was balanced between the established Healthcare franchise and rapid growth in OEM, raw-material and overseas sales. Healthcare represented 92.4% of consolidated revenue and therefore remains the decisive source of growth and earnings. Direct-to-consumer revenue of ¥8.71bn continues to provide scale and a high-value channel, although its 5.2% growth was below total group growth. The 52.0% increase in OEM, raw-material and overseas sales to ¥2.50bn broadens the revenue base beyond direct sales and may improve capacity utilization, but sustained profitability of this mix should be monitored given the Q1 gross-margin decline. Biofuel revenue was ¥0.26bn and remained insufficient to cover segment costs. Other-business revenue declined 0.9% to ¥0.75bn and its loss widened modestly. Full-year revenue guidance is ¥52.0bn and Q1 progress is 25.4%, only 0.4 percentage points above the standard 25% first-quarter run rate. Operating-income progress is 26.2% against the ¥3.20bn full-year target, 1.2 percentage points ahead of the standard run rate. Ordinary-income progress is 27.9% against the ¥2.80bn target, 2.9 percentage points ahead of the standard run rate. These progress rates support the unchanged guidance, but they do not provide a large buffer against weaker gross margins, financing costs, or losses in non-core segments. No extraordinary items were recorded in Q1, improving comparability with the previous year, when restructuring costs depressed pre-tax profit.
Financial Health
Liquidity is adequate but not robust. The current ratio is 117.0% and the quick ratio is 107.9%, so current assets exceed current liabilities, but the current ratio remains below the 1.5x healthy benchmark. Working capital was positive at ¥4.68bn. Cash and deposits of ¥18.87bn were substantial, but were slightly below ¥19.28bn of short-term loans, resulting in a cash-to-short-term-debt ratio of 0.98x. This creates a maturity mismatch risk because 89.2% of interest-bearing debt is short term. Total interest-bearing debt was ¥21.62bn, including ¥19.28bn of short-term loans and ¥2.34bn of long-term loans. Debt-to-capital was 41.2%, slightly above the 40% investment-grade benchmark, while the reported debt-to-equity ratio was 1.29x, below the 2.0x aggressive-financing warning threshold. Interest coverage of 5.54x is adequate, though it should be viewed alongside the high reliance on short-dated funding. Short-term loans increased by ¥15.34bn, or 389.5% YoY, while long-term loans decreased by ¥15.57bn, or 86.9% YoY. This debt-maturity shift is the principal financial-risk development and heightens refinancing sensitivity. Total equity increased ¥2.27bn YoY to ¥30.80bn, improving the capital adequacy ratio to 46.4% from 42.7%. However, non-controlling interests were negative ¥2.04bn, and owners' equity was ¥32.79bn, making attribution and capital-structure analysis more important than the consolidated equity total alone. Acquisition-related and other intangible assets are concentrated at ¥30.38bn, equal to 43.0% of total assets, and goodwill of ¥10.92bn equals 35.5% of equity. The intangible-concentration quality alert is material: asset values and future returns are heavily dependent on the recoverability of acquired brands, customer relationships, technology, and goodwill. Under JGAAP, goodwill amortization reduces operating income and net income relative to IFRS reporters, while impairment remains a downside risk if acquired businesses underperform.
Notable B/S Changes
Short-term loans: +¥15.34bn (+389.5%) to ¥19.28bn - substantial increase in near-term refinancing exposure; cash of ¥18.87bn covers 0.98x of short-term debt. Long-term loans: -¥15.57bn (-86.9%) to ¥2.34bn - indicates a major shortening of the debt-maturity profile and is the key solvency-development to monitor. Retained earnings: +¥3.15bn to ¥0.48bn from negative ¥3.07bn - improved accumulated earnings position, although Q1 profit attributable to owners remained slightly negative. Cash and deposits: -¥2.29bn (-10.8%) to ¥18.87bn - liquidity remains substantial but declined while short-term borrowings increased materially. Intangible assets: -¥0.59bn (-1.9%) to ¥30.38bn, representing 43.0% of total assets - the absolute change was limited, but the asset concentration remains unusually high and heightens amortization and impairment sensitivity. Goodwill: -¥0.18bn (-1.6%) to ¥10.92bn, representing 35.5% of equity - balance-sheet dependence on acquired-business value retention remains elevated.
Cash Flow Quality
Dividend Sustainability
The full-year dividend forecast is ¥0.00 per share. Accordingly, there is no current cash dividend commitment requiring coverage from earnings or free cash flow. Capital allocation flexibility is nevertheless constrained by the need to maintain liquidity against ¥19.28bn of short-term loans and to preserve funding for the operating businesses. Any future shareholder distribution capacity would depend principally on sustained parent-attributable profitability, refinancing execution, and cash generation after operating and investment requirements.
Risk Assessment
Business risks include Healthcare concentration: Healthcare generated 92.4% of Q1 revenue and was the only profitable operating segment, leaving group earnings sensitive to demand, retention, marketing efficiency, and pricing in functional foods and cosmetics., Food and consumer-product cost risk: the gross margin declined 169bp YoY despite revenue growth, exposing earnings to ingredient, packaging, energy, logistics, and foreign-exchange pressures where price pass-through may lag., Inventory risk: the quality alert identifies annualized DIO of 95 days, above the 90-day warning level. Inventories increased 11.7% YoY to ¥2.50bn, and elevated holding periods increase obsolescence, demand-forecasting, and working-capital risk for health-food and cosmetics inventories., Biofuel execution risk: the Biofuel segment posted a ¥0.13bn loss, worse than the ¥0.05bn loss a year earlier. Commercialization timelines, demand formation, project economics, and policy support remain material uncertainties., Brand and channel risk: direct sales remain the largest revenue channel at ¥8.71bn, while rapid OEM/raw-material/overseas growth changes the mix. Competitive intensity, customer concentration in OEM, and overseas market-development costs may affect margins..
Financial risks include Refinancing risk is elevated: 89.2% of interest-bearing debt is short term, short-term loans total ¥19.28bn, and cash covers only 0.98x of this amount., Interest-rate risk: interest expense was ¥0.15bn and interest coverage was 5.54x. Higher rates or reduced operating income would weaken coverage., Intangible asset concentration: intangible assets equal 43.0% of total assets and goodwill equals 35.5% of equity. This raises amortization and potential impairment sensitivity under JGAAP., Tax and attribution risk: income-tax expense was ¥0.43bn on ¥0.78bn of pre-tax income, while non-controlling interests absorbed ¥0.39bn of consolidated profit. As a result, owners recorded a ¥0.03bn loss despite positive operating and ordinary income., Capital-efficiency risk: ROIC of approximately 5.0% is at the lower benchmark boundary, indicating limited return headroom relative to the asset base and debt funding..
Key concerns include Highest priority: successful refinancing or extension of the ¥19.28bn short-term loan balance without a material increase in funding cost., High priority: preservation of Healthcare profitability and gross margin as the group depends on this segment to subsidize Biofuel, Other, and corporate costs., High priority: inventory discipline, given the 95-day inventory holding period and ¥2.50bn inventory balance., Medium priority: recoverability of ¥30.38bn of intangible assets and ¥10.92bn of goodwill if acquired or developed businesses underperform., Medium priority: conversion of consolidated earnings into profit attributable to owners after taxes and non-controlling interests..
Investment Implications
Key takeaways include Q1 operating income growth of 35.4% exceeded revenue growth of 10.6%, driven by SG&A discipline and a 116bp operating-margin expansion., Healthcare is the core business, delivering ¥12.19bn of revenue and ¥1.50bn of segment profit; OEM, raw-material and overseas sales were its fastest-growing channel., The group remains dependent on Healthcare because Biofuel and Other businesses were loss-making., The unchanged full-year plan is broadly supported by Q1 progress: 25.4% for revenue, 26.2% for operating income, and 27.9% for ordinary income., The principal balance-sheet issue is not an outright liquidity deficit but the high concentration of debt in short-term borrowings., Parent shareholders did not participate in Q1 consolidated profitability, with a ¥0.03bn attributable loss despite ¥0.35bn consolidated net income..
Metrics to watch include Healthcare segment revenue growth, segment margin, and the mix between direct sales and OEM/raw-material/overseas sales., Group gross margin and SG&A-to-sales ratio, to determine whether Q1 operating leverage is repeatable., Biofuel segment loss and progress toward an economically viable commercial scale., Short-term loans, cash-to-short-term-debt coverage, interest expense, and interest coverage., Inventory days, inventory balance, and any evidence of markdowns or inventory write-downs., Intangible asset, goodwill, amortization, and impairment trends., Profit attributable to owners relative to consolidated profit, income tax expense, and non-controlling-interest allocation..
Regarding relative positioning, The company has a premium gross-margin profile for a food and consumer-health business, reflecting branded functional products and direct-sales exposure, but its 6.3% operating margin remains below the 8% level generally associated with a stronger profitability profile. Its asset mix is substantially more intangible-heavy than a conventional food manufacturer, and its short-term funding reliance is higher than would be preferred for a consumer-products company with still-developing biofuel operations.